Semaglutide

Overview

Semaglutide is a GLP-1 receptor agonist with 94% amino acid homology to native human GLP-1, modified with a C18 fatty di-acid chain that binds serum albumin to extend its half-life to approximately 7 days. It is FDA-approved as Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral formulation for type 2 diabetes). It has one of the largest clinical trial databases of any modern peptide therapeutic, including the STEP, SUSTAIN, and SELECT trial series.

BLUF — At a Glance

A GLP-1 receptor agonist with high homology to native human GLP-1, extended via albumin binding.

Primary research focus

Glucose-regulation research
Weight-management research
Cardiovascular-outcomes research

Notes: Status: FDA-approved (Rx) — Ozempic, Wegovy, Rybelsus. Half-life ~7 days. Prescription drug; consult a physician.

Mechanism of Action

Semaglutide activates GLP-1 receptors across multiple tissues. In the pancreas, it enhances glucose-dependent insulin secretion from beta cells and suppresses glucagon release from alpha cells. Centrally, it acts on GLP-1 receptors in the hypothalamus and brainstem to reduce appetite and increase satiety signaling. It also slows gastric emptying, contributing to reduced caloric intake. The fatty acid acylation allows albumin binding, protecting against DPP-4 degradation and extending the half-life from ~2 minutes (native GLP-1) to ~168 hours.

Research-Indicated Benefits

Published research suggests significant and sustained weight loss averaging 15-17% of body weight in the STEP trial series
Published research suggests meaningful improvements in HbA1c and glycemic control in type 2 diabetes populations
Published research suggests a 20% reduction in major adverse cardiovascular events (MACE) in the SELECT trial
Published research suggests reductions in appetite and food intake through central and peripheral mechanisms
Published research suggests improvements in cardiometabolic markers including blood pressure, lipid profiles, and inflammatory markers

Typical Research Protocols

Commonly reported in research literature: a dose-escalation schedule starting at 0.25 mg subcutaneously once weekly, titrating monthly through 0.5 mg, 1.0 mg, 1.7 mg, to a maintenance dose of 2.4 mg weekly (weight management indication). The titration approach is critical for GI tolerability, as published data consistently shows gastrointestinal side effects are dose-dependent. The oral formulation (Rybelsus) uses a different dosing paradigm with daily administration.

Important: Semaglutide is an FDA-approved prescription medication (Ozempic, Wegovy, Rybelsus) and should only be used under the supervision of a licensed healthcare provider. The information on this page is provided for educational and research purposes only and is not medical advice.

Safety Profile

Published clinical trials report the following side effects: nausea (most common, typically transient and dose-dependent), vomiting, diarrhea, constipation, and abdominal pain. Rare but serious adverse events identified in trials include pancreatitis, gallbladder disease, and potential thyroid C-cell tumor risk (based on rodent studies; clinical significance in humans not established). The SELECT trial demonstrated cardiovascular safety and benefit. Muscle mass loss concurrent with fat loss has been noted and is an active area of investigation.

Key Studies

Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021 (STEP 1).
Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." New England Journal of Medicine, 2016 (SUSTAIN-6).
Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine, 2023 (SELECT).
Rubino D, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance." JAMA, 2021 (STEP 4).
Knudsen LB, Lau J. "The Discovery and Development of Liraglutide and Semaglutide." Frontiers in Endocrinology, 2019.

Interactions and Stacking

Tirzepatide and Retatrutide are same-class or next-generation incretin receptor agonists that share overlapping mechanisms. AOD-9604 targets weight management through a different pathway (GH fragment lipolysis) and is discussed as a mechanistically complementary option. Tesamorelin addresses body composition through GHRH-mediated pathways rather than GLP-1 signaling. BPC-157 is sometimes discussed in context of GI protection during GLP-1 research protocols due to its gastric cytoprotective research profile.

For research and educational purposes only. Not medical advice.

Frequently Asked Questions

Is Semaglutide FDA-approved?

Yes. Semaglutide is an FDA-approved prescription medication, marketed as Ozempic and Rybelsus for type 2 diabetes and Wegovy for chronic weight management. It should only be used under the supervision of a licensed healthcare provider.

What does the research literature show about Semaglutide?

The published research record for Semaglutide is summarized in the body of this article and the citations section. Pre-clinical and animal-model studies make up the bulk of the literature; human trial data is limited and is noted explicitly where it exists.

What are the documented synergistic compounds for Semaglutide research?

See the Related Research sidebar for compounds that appear alongside Semaglutide in the published literature. Detailed synergy notes will populate during the next vault expansion pass.

Where can I source Semaglutide for research purposes?

See the Where to Source section above for vendors that supply Semaglutide. Listed vendors are affiliate partners of Peptide Manager Pro; we earn a small commission on referred orders at no additional cost to the buyer.